These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23638739)

  • 21. Top stories of 2008. Crash and burn of HIV vaccine candidates.
    del Rio C
    AIDS Clin Care; 2009 Jan; 21(1):4. PubMed ID: 19219958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dynamics of the cellular immune response to HIV infection: implications for vaccination.
    McMichael AJ; Callan M; Appay V; Hanke T; Ogg G; Rowland-Jones S
    Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1007-11. PubMed ID: 11186301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A new veil removed from the physiologic mysteries of "HIV control" ].
    Nau JY
    Rev Med Suisse; 2007 Apr; 3(107):1017. PubMed ID: 17526378
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor HIV control in HLA-B*27 and B*57/58 noncontrollers is associated with limited number of polyfunctional Gag p24-specific CD8+ T cells.
    Techakriengkrai N; Tansiri Y; Hansasuta P
    AIDS; 2013 Jan; 27(1):17-27. PubMed ID: 23079801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HIV-1 vaccine race.
    Ho DD; Huang Y
    Cell; 2002 Jul; 110(2):135-8. PubMed ID: 12150921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
    Stratov I; Dale CJ; Chea S; McCluskey J; Kent SJ
    J Virol; 2005 Jun; 79(12):7728-37. PubMed ID: 15919925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and immune correlates of the HIV infection and vaccine-induced immunity. Foreword.
    Füst G
    Vaccine; 2008 Jun; 26(24):2949-50. PubMed ID: 18321613
    [No Abstract]   [Full Text] [Related]  

  • 29. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
    López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M
    Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.
    Malnati MS; Heltai S; Cosma A; Reitmeir P; Allgayer S; Glashoff RH; Liebrich W; Vardas E; Imami N; Westrop S; Nozza S; Tambussi G; Buttò S; Fanales-Belasio E; Ensoli B; Ensoli F; Tripiciano A; Fortis C; Lusso P; Poli G; Erfle V; Holmes H
    J Immunol Methods; 2012 Jan; 375(1-2):46-56. PubMed ID: 21963950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding what makes a good versus a bad vaccine.
    Harari A; Pantaleo G
    Eur J Immunol; 2005 Sep; 35(9):2528-31. PubMed ID: 16106373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 and AIDS: what are protective immune responses?
    Beattie T; Rowland-Jones S; Kaul R
    J HIV Ther; 2002 May; 7(2):35-9. PubMed ID: 12553686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Protective role of HLA-B27 in HIV and hepatitis C virus infection].
    Neumann-Haefelin C
    Dtsch Med Wochenschr; 2011 Feb; 136(7):320-4. PubMed ID: 21302207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
    Yang OO
    AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.